#Cannabis News: Cannabis
Suisse's (OTC: $CSUI) Own Brand, Alpine Cannabis, is Releasing a Product Line
of Brand-New Cannabis Oils; @SuisseCorp
Dietikon, Switzerland - April 29, 2020
(Investorideas.com Newswire) The booming cannabis industry hasn't been stopped
by the recent outbreak of COVID-19, in fact many sources claim that the nature
of people's self-isolation has boosted the sales in the industry and CBD is
helping people with their fears and anxiety. To differentiate itself from other
Cannabis based companies, Cannabis Suisse Corp (OTC: CSUI) has created some spectacular cannabis products.
Read this news featuring CSUI in full at https://www.investorideas.com/CO/CSUI/news/2020/04291AlpineCannabis.asp
CSUI: Alpine Cannabis
CBD-related products have been increasingly popular
over the recent few years. And it's been happening for a reason. CBD doesn't
get users high and has an ability to treat multiple conditions and diseases.
Apart from that, the U.S. DEA has officially removed the CBD with little to no
THC from their list of controlled substances.
Cannabidiol, also known as CBD, oil can be obtained
from Cannabis plants along with over 100 other compounds. It is widely used in
therapeutics and is known to ease the symptoms of anxiety, epilepsy and even
cancer. As of now, the most significant research confirms positive effects of
CBD oil for patients experiencing seizures (https://www.nature.com/articles/s41598-019-44056-y). Scientists tend to believe that CBD oil helps repress seizures by
slowing down signals that are sent to the brain and by changing levels of
calcium in brain cells thus decreasing inflammation in the brain. Some studies
suggest that CBD may help with diabetes, heart diseases, substance abuse,
mental disorders and certain types of cancers. CBD can have a beneficial effect
on the skin due to anti-inflammatory properties and the ability to control skin
pores and glands.
CBD
products may also contain certain amounts of tetrahydrocannabinol, also known
as THC. THC is a psychoactive cannabinoid found in marijuana. This one causes
the feeling of getting "high", which is usually associated with
marijuana plants.
According
to the latest research by the Global Wellness Institute (GWI), the European CBD
market is projected to surge 400% to at least €1.5 billion by 2023 and it is
suggested that this market could account for over 0.15% of the health and
wellness market value by 2028 (https://globalwellnessinstitute.org/industry-research/2018-global-wellness-economy-monitor/).
The
research conducted by the Brightfield Group and based impending regulatory
changes in EU, the European CBD market is expected to be worth $1.7 billion by
2023. The cannabis market in general is also set to experience rapid growth,
from $318 million in 2018 to nearly $8 billion by 2023.
Currently
European CBD companies have a unique opportunity to operate in a completely
legal market and position themselves as leaders when their country fully
legalizes the use of cannabis. Even when cannabis is completely legal, there
will be a wide market for different CBD products.
Cannabis
Suisse's high-grade cannabis oil will be sold in concentrations of 10%, 15%,
and 25% CBD. It is produced in Switzerland and supplied to both medical and
recreational vendors. However, there are some market and legal restrictions
that may apply outside of Switzerland.
FORWARD-LOOKING
DISCLAIMER
This
press release may contain certain forward-looking statements and information,
as defined within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe
Harbor created by those sections. This material contains statements about
expected future events and/or financial results that are forward-looking in
nature and subject to risks and uncertainties. Such forward-looking statements
by definition involve risks, uncertainties and other factors, which may cause
the actual results, performance or achievements of Cannabis Suisse Corp. to be
materially different from the statements made herein.
More info on CSUI at Investorideas.com Visit: https://www.investorideas.com/CO/CSUI/
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions.
Disclosure
: Cannabis Suisse Corp. (OTC: CSUI) is a paid monthly cannabis company on
Investorideas.com ( five thousand per month) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more
about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global
investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor
Ideas does not condone the use of cannabis except where permissible by law. Our
site does not possess, distribute, or sell cannabis products.
No comments:
Post a Comment